Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Vascular Pharmacology|July 3, 2015
Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndromeMonica Gomaraschi, Alice Ossoli, Maria Pia Adorni, et al.
Biochemical Pharmacology|December 11, 2012
Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplaseMonica Gomaraschi, Alice Ossoli, Cecilia Vitali, et al.
Journal of Lipid Research|October 1, 2020
Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohortChiara Pavanello, Alice Ossoli, Marcello Arca, et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|December 15, 2022
Genetically determined deficiency of ANGPTL3 does not alter HDL ability to preserve endothelial homeostasisAlice Ossoli, Ilenia Minicocci, Marta Turri, et al.
Cardiovascular Research|July 2, 2013
Inflammation impairs eNOS activation by HDL in patients with acute coronary syndromeMonica Gomaraschi, Alice Ossoli, Elda Favari, et al.
Journal of Clinical Medicine|July 26, 2020
Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney DiseaseAndrea Baragetti, Alice Ossoli, Arianna Strazzella, et al.
Pharmacological Research|December 30, 2018
Topiramate protects apoE-deficient mice from kidney damage without affecting plasma lipidsStefano Manzini, Marco Busnelli, Cinzia Parolini, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2020
Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator CompoundChiara Pavanello, Alice Ossoli, Marta Turri, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 22, 2013
Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiencySara Simonelli, Cristina Tinti, Laura Salvini, et al.
Pageof 5